- Home
- PMVP vs IFRX Comparison
PMVP vs IFRX Comparison
Compare PMVP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMVP | IFRX |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | Germany |
| Employees | N/A | 74 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.0M | 81.3M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PMVP | IFRX |
|---|---|---|
| Price | $1.19 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | 217.0K | ★ 647.3K |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $73,729.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,054.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.81 | $0.71 |
| 52 Week High | $1.84 | $2.77 |
Technical Indicators
Market Signals| Indicator | PMVP | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.61 | 49.25 |
| Support Level | $1.20 | $0.99 |
| Resistance Level | $1.26 | $1.16 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 47.16 | 50.00 |
Price Performance
Historical ComparisonAbout PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.